CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy
Treatment of advanced stage cervical and ovarian cancer
Treatment of advanced stage breast cancer
Cancer genetics in the clinic: Ready for 'prime time'?
The National Cancer Grid of India
Setting the goals of care
Diagnosis and staging of lung adenocarcinoma
Epidemiology and outcomes of cancer in India
Treatment of late stage adenocarcinoma
Diagnosis and staging of cervix and ovarian cancers
Diagnosis and staging of oral cancer